FREQUENT BASELINE EGFR MUTATION T790M IN CYTOLOGICAL SPECIMENS OF TYROSINE KINASE INHIBITOR (TKI) NAIVE ADENOCARCINOMA NSCLC PATIENTS

被引：0
|
作者：
Andarini, S. L. [1 ]
Zaini, J. [1 ]
Hudoyo, A. [1 ]
Hidayat, H. [1 ]
Widjajahakim, G. [2 ]
Utomo, A. R. [3 ]
机构：
[1] Univ Indonesia, Persahabatan Hosp, Dept Pulmonol & Resp Med, Fac Med, Jakarta, Indonesia
[2] KalGen Lab, Pathol Core Facil, Jakarta, Indonesia
[3] KalGen Lab, Stem Cell & Canc Inst, Canc Diagnost Res, Jakarta, Indonesia
来源：
RESPIROLOGY | 2016年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
APSR6-0587
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [31] Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR-Mutated Lung Cancer
    Haratake, Naoki
    Misumi, Toshihiro
    Yamanaka, Takeharu
    Seto, Takashi
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [32] T790M MUTATION IN PATIENTS WITH ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS: IS IT ASSOCIATED WITH CLINICALLY DISTINCT FEATURES?
    Ji, Jun Ho
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Choi, Yoon-La
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1073 - S1073
  • [33] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [34] Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report
    Bruno, Rossella
    Proietti, Agnese
    Ali, Greta
    Puppo, Gianfranco
    Ribechini, Alessandro
    Chella, Antonio
    Fontanini, Gabriella
    ONCOLOGY LETTERS, 2017, 14 (05) : 5947 - 5951
  • [35] Selective pressure for the EGFR T790M resistance mutation may be different for different EGFR tyrosine kinase inhibitors
    Chmielecki, Juliann
    Pietanza, Maria C.
    Kris, Mark
    Miller, Vincent
    Pao, William
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S250 - S250
  • [36] The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
    Tseng, Jeng-Sen
    Su, Kang-Yi
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Hsu, Kuo-Hsuan
    Chen, Hsuan-Yu
    Tsai, Chi-Ren
    Yu, Sung-Liang
    Chang, Gee-Chen
    ONCOTARGET, 2016, 7 (30) : 48059 - 48069
  • [37] Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naive patients with non-small cell lung cancer harboring EGFR mutations
    Tanaka, Kentaro
    Nosaki, Kaname
    Otsubo, Kohei
    Azuma, Koichi
    Sakata, Shinya
    Ouchi, Hiroshi
    Morinaga, Ryotaro
    Wataya, Hiroshi
    Fujii, Akiko
    Nakagaki, Noriaki
    Tsuruta, Nobuko
    Takeshita, Masafumi
    Iwama, Eiji
    Harada, Taishi
    Nakanishi, Yoichi
    Okamoto, Isamu
    ONCOTARGET, 2017, 8 (40) : 68123 - 68130
  • [38] Detection of EGFR/T790M Mutation in Advanced NSCLC Post TKI Treatment: First Experience of Liquid Biopsy in Argentina
    Mosqueira, M. C.
    Anchordoqui, S.
    Martinez Correa, R.
    Pichelbauer, E.
    Trinchero, A.
    Bianchini, M.
    Bravo, I.
    Bramuglia, G.
    Diaz Perez, I.
    Sganga, L.
    Goncalves, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S166 - S167
  • [39] Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
    Yang, Zhengquan
    Li, Jialu
    Hu, Yujie
    Chen, Meihua
    Peng, Danli
    Zong, Dan
    Shang, Qingjuan
    Tao, Lianqin
    Zhao, Yanling
    Ni, Yiyun
    Ye, Jinyan
    Xie, Yupeng
    Yang, Li
    Lin, Quan
    Cai, Chang
    Xu, Ning
    Huang, Xiaoping
    Dong, Xiaoting
    Zhou, Zhonghui
    Yu, Yali
    Shangguan, Zongxiao
    Xu, Yangyang
    Ying, Weiping
    Weng, Meiling
    Yuan, Zuguo
    Dong, Zhijun
    Li, Jifa
    Zheng, Zhe
    Pan, Jiongwei
    Liu, Lu
    Ye, Junhui
    Zhang, Zhan
    Li, Wenfeng
    Zhu, Junfei
    Jin, Shengnan
    Li, Yuping
    Ding, Chunming
    TARGETED ONCOLOGY, 2019, 14 (06) : 719 - 728
  • [40] The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
    Sato, Yuki
    Masuda, Takeshi
    Miura, Satoru
    Tachihara, Motoko
    Hosokawa, Shinobu
    Nakamura, Atsushi
    Miyawaki, Taichi
    Yoshimine, Kohei
    Mori, Masahide
    Shiraishi, Hideaki
    Hamai, Kosuke
    Haratani, Koji
    Maeda, Sumiko
    Tabata, Eriko
    Kitagawa, Chiyoe
    Tanizaki, Junko
    Imai, Takumi
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hattori, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345